Physician profile
James E Turner
NPI 1174542476
$1,962.93
in general payments reported to CMS, 2019-2025
26 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,011 · 2020: $99.72 · 2021: $352 · 2022: $26.22 · 2023: $240 · 2024: $130 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461 · Education: $13.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.27 |
| Education | $13.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $225.44 | 2021-2024 | Myrisk |
| Merck Sharp & Dohme LLC | $217.63 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Seagen INC. | $213.40 | 2019-2022 | |
| Pfizer INC. | $195.01 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $162.08 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $139.88 | 2019 | |
| Amgen INC. | $130.69 | 2019-2023 | Kyprolis, Blincyto |
| Novartis Pharmaceuticals Corporation | $111.94 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $67.54 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $60.96 | 2019-2025 | Libtayo |
| Alnylam Pharmaceuticals INC. | $59.28 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $40.56 | 2019-2020 | |
| Tesaro, INC. | $39.92 | 2019 | |
| Amag Pharmaceuticals, INC. | $35.76 | 2019 | |
| Genentech USA, INC. | $32.81 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29.45 | 2019-2025 | |
| Heron Therapeutics, INC. | $29.39 | 2019-2020 | |
| Verastem, INC. | $25.05 | 2019 | |
| Astellas Pharma US INC | $24.97 | 2019 | |
| Glaxosmithkline, LLC. | $24.81 | 2024 | Ojjaara |
| Ethicon US, LLC | $20.52 | 2019 | |
| Eisai INC. | $17.17 | 2020 | |
| Coherus Oncology, INC. | $16.45 | 2023 | |
| Celgene Corporation | $15.68 | 2019 | |
| Array Biopharma INC | $14.57 | 2021 | |
| Exelixis INC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.